Shengdar Tsai, Associate Member at St. Jude Children’s Research Hospital, shared a post on LinkedIn:
“I am thrilled to share the wonderful news that our St. Jude-led performer team, DRIVE (Delivering Rare-Disease In Vivo Editors), has been selected for an ARPA-H award up to $28.5M to advance personalized, curative medicines through in vivo genome editing for patients with bone marrow failure disorders.
We are looking forward to working with our incredible partners, ARPA-H, and other select performer teams towards our shared vision of developing therapeutic genome-editing platforms to treat rare genetic diseases.”
Other articles on OncoDaily.